Aegis Capital Corp. Reiterates on Amarin Corporation plc After FDA Formally Rescinds Special Protocol Assessment

In a report published Wednesday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Hold rating on Amarin Corporation plc (NASDAQ: AMRN ). In the report, Aegis Capital Corp. noted, “Yesterday, Amarin disclosed via 8-K filing that the FDA had notified it of the formal rescinding of the original Special Protocol